HBOT for Longevity & Performance: Anti-Aging Evidence & What the Research Actually Shows

A 2020 prospective trial of 35 healthy adults over age 64 found that 60 hyperbaric oxygen sessions increased telomere length by more than 20 percent in immune cells and cut senescent T-helper cells by 37.3 percent (Hachmo et al., Aging, 2020). Those are the headline numbers behind HBOT longevity claims. Nearly all of this data comes from one research group in Israel, no independent lab has replicated it, and the flagship telomere study had no control group.

The idea that a course of hyperbaric oxygen can slow or reverse biological aging rests on a small cluster of human trials, most of them from Professor Shai Efrati’s group at Shamir Medical Center. The findings are real and were published in peer-reviewed journals. They are also early, small, and largely unreplicated. This guide separates what the studies measured from what the marketing implies, so you can judge whether a $9,000 to $18,000 protocol is worth it for you.

Does HBOT Lengthen Telomeres?

One uncontrolled trial found it can. Hachmo et al. (Aging, 2020) reported that 60 daily HBOT sessions increased telomere length by more than 20 percent across four immune cell types in 35 adults over 64. There was no control group and no independent replication, so the result is promising but not established.

The study enrolled 35 healthy, independently living adults aged 64 and older who underwent 60 daily HBOT sessions at 2 ATA (atmospheres absolute) with 100 percent medical-grade oxygen, 90 minutes per session, five days per week. Telomere length increased across T-helper, T-cytotoxic, natural killer, and B cells, with B cells showing the largest gain at 37.63 percent. Senescent T-helper cells fell 37.30 percent (P<0.0001) and senescent T-cytotoxic cells fell 10.96 percent (p=0.0004).¹

Telomere attrition and cellular senescence are two of the recognized hallmarks of aging (López-Otín et al., Cell, 2013), which is why these numbers drew worldwide headlines about reversing aging.¹⁴ Several caveats are essential before reading them that way:

• No control group. This was a single-arm prospective study. Some of the change could reflect measurement variability or regression to the mean rather than a true biological effect.
• No independent replication. Every telomere and senescence finding here comes from the same center. A result becomes robust when a separate lab reproduces it, and that has not happened.
• High variability. The B-cell telomere change was 37.63 percent plus or minus 52.73 percent. The standard deviation exceeds the mean, meaning individual responses ranged from large gains to none.
• Unknown durability. No follow-up data shows whether these changes persist at 6, 12, or 24 months after the protocol ends.

Telomere length is also only one marker of aging, and it correlates weakly with the epigenetic clocks now considered the reference standard for biological age. For the full breakdown of this trial and the numbers behind it, see our detailed HBOT anti-aging telomere data analysis. The broader case for and against HBOT as an anti-aging intervention is covered separately.

Can HBOT Reverse Skin Aging?

A small biopsy study suggests measurable tissue changes. Hachmo et al. (Aging, 2021) took skin biopsies from 13 men (mean age 68) before and after the same 60-session protocol and found increased collagen density, longer elastic fibers, more blood vessels, and fewer senescent cells. The sample was tiny, all male, and uncontrolled, so this is early tissue-level evidence rather than proof of cosmetic benefit.

Specifically, collagen density rose (p<0.001, effect size 1.10), elastic fiber length rose (p<0.0001, effect size 2.71), blood vessel number rose (p=0.02), fiber fragmentation fell, and senescent cell density in the skin decreased (p=0.03).² This was the first demonstration of HBOT modulating skin aging at the structural level in humans.

A 2024 systematic review of HBOT in aesthetic medicine (Fisher et al., Aesthetic Plastic Surgery) found the overall evidence base for anti-aging and cosmetic use to be limited and heterogeneous, drawn largely from small studies.¹² The structural gains are the basis for growing interest in the hyperbaric chamber for skin rejuvenation, but that cosmetic evidence remains early. The same VEGF-driven increase in local blood supply is why some clinics also explore the hyperbaric chamber for hair growth, where follicles depend on rich perfusion.

Does HBOT Improve Physical Performance?

This is the strongest part of the evidence. Two randomized controlled trials, both from the Efrati group, found HBOT raised maximal oxygen uptake (VO2Max) versus a sham or control condition. A 2024 RCT in older adults and a 2022 RCT in masters athletes both showed measurable aerobic gains, which puts performance ahead of the anti-aging biomarkers on evidence quality.

The 2024 trial (Hadanny et al., BMC Geriatrics) randomized 63 adults over 64: 30 received 60 HBOT sessions at 2 ATA over 12 weeks and 33 served as controls.⁴ Results reached significance across several measures:

• VO2Max per kilogram rose by 1.91 ml/kg/min (effect size 0.455, p=0.0034)
• VO2 at the first ventilatory threshold rose by 160 ml/min (effect size 0.617, p<0.001)
• Myocardial blood flow (MBF) increased (effect size 0.797, p=0.008)
• Myocardial blood volume (MBV) increased (effect size 0.896, p=0.009)

A separate double-blind RCT (Hadanny et al., Sports Medicine – Open, 2022) tested 37 healthy masters athletes aged 40 to 50 across 40 sessions of either HBOT at 2 ATA or a sham exposure at 1.02 ATA breathing air. The HBOT group showed significant increases in VO2Max, VO2 at the anaerobic threshold, and mitochondrial respiration measures including complex I function, compared with sham.¹⁸

Because these are controlled and randomized, the performance findings are the most credible in the whole longevity picture. The trade-off is that both trials still come from a single center, use the same intensive protocol, and have not been reproduced elsewhere. For the applied side of this, see our data on HBOT athletic recovery and whether the hyperbaric chamber for athletes earns its cost.

Does HBOT Improve Cognition in Older Adults?

One randomized controlled trial found gains. Hadanny et al. (Aging, 2020) randomized 63 healthy adults over 64 to HBOT or a control period and reported improved global cognition, attention, and processing speed, correlated with increased cerebral blood flow. It is a single-group RCT with no independent replication, so the effect is emerging rather than established.

The trial found a significant group-by-time interaction in global cognitive function favoring HBOT (p=0.0017), with the largest effects in attention (net effect size 0.745) and information processing speed (net effect size 0.788).⁹ These domains typically decline with age, and the improvements tracked with measured increases in cerebral blood flow. A 2022 case report in which a neurosurgeon self-administered 60 sessions described improved cognition and brain perfusion alongside a reported doubling of telomere length, but as a single-subject report (n=1) it carries no statistical weight and is included only as context.⁵ Related mechanisms are explored in our coverage of HBOT and cellular aging.

How Would HBOT Slow Aging?

The leading explanation is the hyperoxic-hypoxic paradox. Repeated sessions of high oxygen, followed by a return to normal air, create a relative drop in oxygen that the body reads as a hypoxic signal. That signal activates HIF-1-alpha and related repair pathways without the tissue damage true oxygen deprivation would cause (Hadanny and Efrati, Biomolecules, 2020).

When an HBOT session ends and the patient returns to atmospheric conditions, the sharp fall in tissue oxygen mimics hypoxia. This activates HIF-1-alpha, the same transcription factor triggered by altitude training, which in turn stimulates VEGF, erythropoietin, and mobilization of stem and progenitor cells.¹⁰ Thom et al. showed that a single 2 ATA exposure roughly doubled circulating CD34+ stem cells in humans, with an eightfold increase over 20 treatments (Am J Physiol Heart Circ Physiol, 2006), and later work tied HBOT to vasculogenic stem cell recruitment in patients.¹³¹¹ Sunkari et al. (Wound Repair and Regeneration, 2015) demonstrated that HBOT increases HIF-1-alpha stability and activity, driving angiogenesis.²⁰

“Intermittent hyperoxia induces many of the same cellular and physiological responses as hypoxia, including HIF-1-alpha activation, but in a controlled and tolerable manner.”
Hadanny and Efrati, Biomolecules, 2020

A proposed distinction from true hypoxia is that HBOT also induces SIRT1, a longevity-associated enzyme that is reduced during genuine oxygen deprivation. Kamat et al. (Rejuvenation Research, 2021) argued that dual activation of HIF-1-alpha and SIRT1 may explain why intermittent hyperoxia produces rejuvenation-associated signals rather than damage.⁶ Reviews of HBOT mechanisms describe parallel effects on mitochondrial function and oxidative stress balance, including upregulation of Nrf2 antioxidant pathways (Schottlender et al., Biomolecules, 2021; Fu et al., Redox Biology, 2022).¹⁶⁷ Efrati et al. (PLoS ONE, 2013) had earlier shown HBOT could induce neuroplasticity in chronic post-stroke patients, supporting the idea that the therapy drives tissue-level change well after an initial injury.¹⁹

These mechanisms are biologically plausible and supported by both animal and human data. What they do not yet prove is that activating these pathways for 60 sessions translates into a longer or healthier life. Mechanism is not outcome.

What Do the Gene Expression Data Show?

One trial found broad transcriptome changes. Hadanny et al. (Aging, 2021) analyzed blood from 35 adults in the telomere cohort and found 1,912 genes differentially expressed after 60 HBOT sessions. It is direct molecular evidence that HBOT alters gene activity, but it is a single uncontrolled study and does not by itself demonstrate slower aging.

Of the 1,912 differentially expressed genes, 1,342 were upregulated and 570 downregulated (p<0.01, false discovery rate corrected).³ This was the first report of HBOT-associated transcriptome changes in humans. The same limitations apply as to the telomere work: one center, one cohort, no control arm, no replication. Differential gene expression confirms the body responds to the protocol; it does not establish that the response extends lifespan or healthspan.

What Is Missing From the Longevity Evidence?

The biggest gap is biological age itself. No published study has shown HBOT reverses aging as measured by DNA methylation clocks such as Horvath or GrimAge, which are the reference standard for biological age (López-Otín et al., Cell, 2023). Add the absence of long-term follow-up and independent replication, and the honest verdict is emerging, not proven.

The table below synthesizes every measured longevity outcome against the quality of the evidence behind it. It is built from the primary trials rather than any single competitor source, and it doubles as the credibility check on the headline claims.

Three structural weaknesses run through almost every row. First, single research group. Nearly all human longevity data comes from Efrati’s team at Shamir Medical Center. Second, no long-term follow-up. No trial reports whether telomere, senescence, or performance gains persist beyond the treatment window. Third, no epigenetic age endpoint. The one measurement that would most directly test the anti-aging claim has not been published. Until independent labs reproduce these results and add durable, clock-based endpoints, HBOT longevity should be read as a promising hypothesis under active study.

Does Mild or Home HBOT Offer the Same Longevity Benefits?

There is no evidence that it does. Every published longevity and performance trial used hard chambers at 2 ATA with 100 percent medical oxygen. Mild HBOT at around 1.3 ATA, common in soft home chambers with ambient or concentrated air, has never been tested against telomere, senescence, VO2Max, or cognitive endpoints, so its longevity benefit is unproven.

The distinction matters because the two are often marketed as interchangeable. The physical dose of oxygen delivered to tissue depends on both pressure and oxygen concentration, and the gap between a 1.3 ATA air chamber and a 2 ATA pure-oxygen chamber is large. The hyperoxic-hypoxic paradox proposed by Hadanny and Efrati (Biomolecules, 2020) depends on reaching a high enough tissue oxygen level that the return to normal air registers as a meaningful hypoxic signal.¹⁰ Whether milder exposures cross that threshold is unknown, because no dose-response study has been run. A buyer choosing a home unit for longevity is extrapolating well beyond the data. For a direct comparison of the two approaches, see our recovery data breakdown, which covers where soft chambers do and do not have support. Anyone weighing a purchase should treat clinical 2 ATA protocols and home soft chambers as separate interventions with separate, and unequal, evidence bases.

What Are the Risks and Trade-offs of Elective HBOT?

HBOT is generally well tolerated at therapeutic pressures, but it is not risk-free, and longevity use is elective rather than medically necessary. The most common side effect is middle-ear barotrauma from pressure changes. Rarer risks include temporary near-sightedness, and, uncommonly at 2 ATA, oxygen-toxicity seizures.

For an elective longevity course, three trade-offs stand out. The first is time: 60 sessions of 90 minutes over about 12 weeks is a large commitment. The second is cost: at $150 to $300 per session, the protocol runs $9,000 to $18,000 out of pocket, since insurers do not cover longevity or performance use. The third is opportunity cost against interventions with far stronger mortality evidence, such as resistance and aerobic exercise, which improve VO2Max and healthspan through well-replicated trials. HBOT’s longevity data, by contrast, rests on surrogate markers from a single group. None of this makes the therapy unsafe. It makes the value proposition uncertain, which is the honest framing for a decision this expensive.

What Does the Longevity Protocol Involve and Cost?

Every anti-aging HBOT study used the same regimen: 60 daily sessions at 2 ATA with 100 percent medical-grade oxygen, about 90 minutes each, five days a week for roughly 12 weeks. At typical clinic pricing of $150 to $300 per session, that is a $9,000 to $18,000 course. No dose-finding study has tested whether fewer sessions would work.

This protocol is not the same as the mild HBOT (around 1.3 ATA) offered in many wellness centers using soft chambers with ambient air. Every published aging trial used hard chambers at 2 ATA with medical-grade oxygen. Whether lower pressures produce any anti-aging signal is untested, which matters for anyone comparing a clinic course against a home soft chamber. For current pricing detail, see our hyperbaric chamber cost guide, and for what payers will and will not cover, the HBOT insurance guide. Longevity and performance use is elective, so expect to pay out of pocket. The FDA has publicly warned that HBOT is marketed for many conditions where it is not proven or approved, longevity among them.²¹

Sources